ArticleBiomaterials2015
In situ gelling silk-elastinlike protein polymer for transarterial chemoembolization.
Article in Biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Advancements in hydrogel-based embolic agents: Categorized by therapeutic mechanisms.Cancer medicine · 2024Pooled it
- Bioengineered elastin- and silk-biomaterials for drug and gene delivery.Advanced drug delivery reviews · 2020Pooled it
- Functionalized biomaterial platforms for interventional embolization therapy of hepatocellular carcinoma.Bioactive materials · 2027Review
- Therapeutic embolic agents for targeted drug delivery in transcatheter therapies: a review.Chemical communications (Cambridge, England) · 2026Review
- Genetically Fusing Order-Promoting and Thermoresponsive Building Blocks to Design Hybrid Biomaterials.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024Review
- Matrix-Mediated Delivery of Silver Nanoparticles for Prevention ofPharmaceutics · 2023Article
- Liquid Embolic Agents for Endovascular Embolization: A Review.Gels (Basel, Switzerland) · 2023Review
- Article
- Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma.Journal of nanobiotechnology · 2023Review
- Material characterization of GPXFrontiers in bioengineering and biotechnology · 2023Article
- Hydrogel systems for targeted cancer therapy.Frontiers in bioengineering and biotechnology · 2023Review
- Interventional oncology: new techniques and new devices.The British journal of radiology · 2022Review
- Emerging Polymer Materials in Trackable Endovascular Embolization and Cell Delivery: From Hype to Hope.Biomimetics (Basel, Switzerland) · 2022Review
- Nanotechnology in the Diagnostic and Therapy of Hepatocellular Carcinoma.Materials (Basel, Switzerland) · 2022Review
- Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Translational Development of a Silk-Elastinlike Protein Polymer Embolic for Transcatheter Arterial Embolization.Macromolecular bioscience · 2022Article
- An Oligomeric Sulfated Hyaluronan and Silk-Elastinlike Polymer Combination Protects against Murine Radiation Induced Proctitis.Pharmaceutics · 2022Article
- Evaluation of the safety and efficacy of transarterial sevelamer embolization in a rabbit liver cancer model: A challenge on the size rule for vascular occlusion.Frontiers in bioengineering and biotechnology · 2022Article
- Development of cisplatin-loaded hydrogels for trans-portal vein chemoembolization in an orthotopic liver cancer mouse model.Drug delivery · 2021Article
- Dynamically tunable light responsive silk-elastin-like proteins.Acta biomaterialia · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Hepatocellular carcinoma annually affects over 700,000 people worldwide and trends indicate increasing prevalence. Patients ineligible for surgery undergo loco-regional treatments such as transarterial chemoembolization (TACE) to selectively target tumoral blood supply. Using a microcatheter, chemotherapeutics are infused followed by an embolic agent, or the drug is encapsulated by the embolic moiety; simultaneously inducing stasis while delivering localized chemotherapy. Presently, several products are used, but no universally accepted system is promoted because very disparate limitations exist. The goal of this investigation was to design and develop in situ gelling recombinant silk-elastinlike protein polymers (SELPs) for TACE. Two SELP compositions, SELP-47K and SELP-815K, with varying lengths of silk and elastin blocks, were investigated to formulate a new embolic that was injectable through commercially available microcatheters. The goal was to develop a composition providing maximal permeation of tumor vasculature while exhibiting effective embolic activity. The SELPs evaluated remain soluble until reaching 37 °C, when irreversible transition ensues forming a solid hydrogel network. SELP-815K formulated at 12% w/w with shear processing demonstrated acceptable rheological properties and clear embolic capability under flow conditions in vitro. A rabbit model showed feasibility of embolization in vivo allowing selective occlusion of lobar hepatic arterial branches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.